Adverse reaction report
MENU
2023.06.05
Recently,Food and Drug Administration (FDA) approved SinoT’s ANDA(# 214496)application for PREGABALIN EXTENDED-RELEASE TABLETS(82.5 mg, 165 mg, and 330 mg)
Read More
2023.05.15
Recently,Food and Drug Administration (FDA) approved SinoT’s ANDA(#217337)application for Mesalamine, delayed-release tablets(1.2g).
2022.08.25
Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA
2022.04.07
Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been granted approval from the Health Sciences Authority (HSA) in Singapore.
2021.11.02
Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Bupropion hydrochloride extended-release tablets (XL)(150mg,300mg), this product has already been approved in FDA on August 2017.
2021.08.12
On August 11, 2021,Food and Drug Administration (FDA) approved SinoT’s ANDA(#213612)application for Paroxetine hydrochloride extended-release tablets(12.5mg,25mg).
2021.01.26
Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Posaconazole delayed-release tablets (100mg), this product has already been approved by FDA on August 2019 as the first generic drug.
2019.08.16
The US FDA conducted an onsite inspection of our R&D Center located in Shanghai between Aug 12 and Aug 16, 2019.
Shanghai Head Office
86 21-6881-9009
Greenland Being Fun Plaza, Bldg. 1, Rm. 207, Pudong New District, Shanghai
Manufacturing Site inJiangsu
86 513-8122-1988
No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province
Focus on us
Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP:13048014-1 Powered by Yongsy
Privacy Legal